Risks and benefits of hormone replacement therapy: The evidence speaks

CMAJ. Canadian Medical Association Journal

Volumn 168, Issue 8, 2003, Pages 1001-1010

  Humphries, Karin H ^a   Gill, Sabrina ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLONIDINE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ANDROGEN THERAPY; BONE DENSITY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CASE REPORT; CLINICAL TRIAL; COGNITION; COLON CANCER; CORONARY ARTERY DISEASE; DEMENTIA; DRUG EFFECT; DYSLIPIDEMIA; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; FRACTURE; GALLBLADDER DISEASE; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; OSTEOPOROSIS; OVARY CANCER; POSTMENOPAUSE; REVIEW; THROMBOEMBOLISM;

EID: 0037447523     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Greendale G, Reboussin B, Hogan P. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982-88.
2. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-7.
3. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998;19:55-72.
4. Grady D, Rubin S, Petitti D, Fox CS, Black D, Ettingher B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
5. Stampfer M, Colditz G. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.
6. Anderson H. Estrogen therapy, atherosclerosis, and clinical cardiovascular events. Circulation 1996;94:1809-11.
7. Mosca L. Estrogen and atherosclerosis. J Invest Med 1998;46:381-6.
8. Guetta V, Cannon R. Cardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation 1996;93:1928-37.
9. Mendelsohn M, Karas R. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801-11.
10. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
11. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy (HERS II). JAMA 2002;288:49-57.
12. Viscoli C, Brass L, Kernan W, Sarrel P, Suissa S, Horowitz R. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243-9.
13. Simon J, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen/progestin Replacement Study (HERS). Circulation 2001;103:638-42.
14. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
15. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Scholfiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002;109:1056-62.
16. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions Trial. JAMA 1995;273:199-208.
17. Herrington D, Reboussin D, Brosnihan B, Sharp PC, Shumaker SA, Snyder TE, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-9.
18. Hodis H, Mack W, Lobo R, Shoupe D, Sevanian A, Mahrer PR, et al. Estrogen in the Prevention of Atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53.
19. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40.
20. Mosca L, Collins P, Herrington D, Mendelsohn ME, Pasternak RC, Robertson RM, et al. Hormone replacement therapy and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 2001;104:499-503.
21. Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, et al. Metaanalyses of therapies for postmenopausal women. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23(4):529-39.
22. Villareal D, Binder E, Williams D, Schechtman K, Yarasheski K, Kohrt W. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA 2001;286:815-20.
23. Lufkin E, Wahner H, O'Fallon W. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
24. Wimalawansa S. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998;104:219-26.
25. Komulainen M, Kroger H, Tuppurainen M, Heikkinen AM, Alhava E, Honkanen R, et al. HRT and vitamin D in prevention of non-vertebral fractures in postmenopausal women: a 5 year randomized trial. Maturitas 1998;31:45-54.
26. Mosekilde L, Beck-Nielsen H, Sorensen OH, Nielsen SP, Charles P, Vestergaard P, et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas 2000;36:181-93.
27. Cauley J, Black D, Barrert-Connor E, Harris F, Shields K, Applegate W, et al. The effects of hormone replacement therapy on clinical fractures and height loss: the Heart and Estrogen/progestin Replacement Study. Am J Med 2001;110:442-50.
28. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. HERS II. JAMA 2002;288:58-66.
29. Windeler J, Lange S. Events per person year: a dubious concept. BMJ 1995;310:454-6.
30. Torgerson D, Bell-Syer S. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-7.
31. US Food and Drug Administration. FDA approves new labels for estrogen and estrogen with progestin therapies for postmenopausal women following review of Women's Health Initiative data [press release PO3-01]. FDA News 2003 Jan 8. Available: www.fda.gov/bbs/topics/NEWS/2003/NEW00863.html (accessed 2003 Mar 12).
32. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(Suppl 10):S1-34.
33. McClung M, Geusens P, Miller P, Zippel H, Benson WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
34. FIT Research Group. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-24.
35. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
36. Chesnut CH III, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76.
37. Smith CA, McCleary CA, Murdock GA, Wilshire TW, Buckwalter DK, Bretsky P, et al. Lifelong estrogen exposure and cognitive performance in elderly women. Brain Cogn 1999;39:203-18.
38. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288:2123-9.
39. Phillips S, Sherwin B. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-95.
40. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345-57.
41. Fedor-Freybergh P. The influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scund Suppl 1977;64:1-91.
42. Ditkoff E, Crary W, Cristo M, Lobo R. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991;78:991-5.
43. Hackman B, Galbraith D. Replacement therapy and piperazine oestrone sulphate and its effect on memory. Curr Med Res Opin 1976;4:303-6.
44. Caldwell B, Watson R. An evaluation of psychological effects of sex hormone administration in aged women: results after six months. J Gerontol 1952;7:228-44.
45. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol 1977;4:31-47.
46. Honjo H, Ogino Y, Niatoh K, Urabe M, Kitawaki J, Yasuda J, et al. In vivo effects by estrone sulfate on the central nervous system-senile dementia (Alzheimer's type). J Steroid Biochem 1989;34(1-6):521-5.
47. Fillit H, Weinreb H, Cholst I, Luine V, McEwen B, Amador R, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986;11:337-45.
48. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N, et al. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J 1994;41:361-71.
49. Honjo H, Ogino Y, Naitoh K, et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: a placebo-controlled double blind study. J Jpn Menopause Soc 1993;1:167-71.
50. Shumaker SA, Reboussin BA, Espeland MA, Rapp SR, McBee WL, Dailey M, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Controlled Clin Trials 1998;19:604-21.
51. Clemons M, Goss P. Mechanisms of disease: estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
52. Rosner B, Colditz G, Willett W. Reproductive risk factors in a prospective study of breast cancer: Nurses' Health Study. Am J Epidemiol 1994;139:819-35.
53. Colditz G, Egan K, Stampfer M. Hormone replacement therapy and risk of breast cancer. Results of epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-80.
54. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative re-analysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
55. Steinberg KK, Smith SJ, Thacker SB, Stroup DF. Breast cancer risk and duration of estrogen use: the role of study design in meta-analysis. Epidemiology 1994;5:415-21.
56. Steinberg K, Thacker S, Smith S, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement on the risk of breast cancer. JAMA 1991;265:1985-90.
57. Boyd N, Byng J, Jong R, Fishell EK, Little LE, Miller AB, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-5.
58. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-91.
59. Santen R, Pinkerton J, McCartney C, Petroni G. Clinical review: risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab 2001;86:16-23.
60. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami H, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339-44.
61. Ross R, Paganini-Hill A, Wan P, Pike M. Effect of hormone replacement therapy on breast cancer risk: estrogen vs estrogen plus progestin. J Natl Cancer Inst 2000;92:328-32.
62. Sellers T, Mink P, Cerhan J, Zheng W, Anderson KE, Kushi LH, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127:973-80.
63. Hoskins K, Stopfer J, Calzone K, Merajver SD, Rebbeck TR, Garber JE, et al. Assessment and counseling for women with a family history of breast cancer. A guide for clinicians. JAMA 1995;273:577-85.
64. Vassilopoulou-Sellin R, Asmar L, Hortobagyi G, Klein MJ, McNeese M, Singletary SE, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J Clin Oncol 1999;17:1482-7.
65. DiSaia P, Grosen E, Kurosaki T, Gildea M, Cowan B, Anton-Culver H. Hormone replacement therapy in breast cancer survivors: a cohort study. Am J Obstet Gynecol 1996;174:1494-8.
66. Cobleigh M, Berris R, Bush T, Davidson NE, Robert NJ, Sparano JA, et al. Estrogen replacement therapy in breast cancer survivors: a time for change. JAMA 1994;272:540-5.
67. Treatment of estrogen deficiency symptoms in women surviving breast cancer. J Clin Endocrinol Metab 1998;83:1993-2000.
68. Loprinzi C, Kugler J, Sloan J, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63.
69. Loprinzi CL, Barton D. Estrogen deficiency: in search of symptom control and sexuality [editorial]. J Natl Cancer Inst 2000;92:1028-9.
70. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994,344:1383-9.
71. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
72. Lethaby A, Farquhar C, Sarkis A, Roberts H, Jepson R, Barlow D. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding [Cochrane review]. In: Cochrane Database of Systematic Reviews; 2000(2): CD000402. Oxford: Update Software.
73. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996;275:370-5.
74. Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:680-90.
75. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Posmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.
76. Perez G, Garcia R, Castellsague J, Duque O. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997;314:796-800.
77. Hoibraaten E, Qvigstad E, Amesen H, Larsen S, Wickstrom E, Sandset P. Increased risk of recurrent venous thromboembolism during hormone replacement therapy - results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000;84:961-7.
78. Giltay EJ, Gooren LJ, Emeis JJ, Kooistra T, Stehouwer CD. Oral, but not transdermal, administration of estrogens lowers tissue-type plasminogen activator levels in humans without affecting endothelial synthesis. Arterioscler Thromb Vasc Biol 2000;20:1396-403.
79. Scarabin P, Alhenic-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-8.
80. North American Menopause Society. A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: consensus opinion of the North American Menopause Society. Menopause 2000;7:76-86.
81. Creinin M, Lisman R, Strickler R. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999;72:646-51.
82. Grodstein F, Colditz G, Stampfer M. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994;83:5-11.
83. Nanda K, Bastian L, Hasselblad V. Hormone replacement and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol 1999;93:880-8.
84. Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med 1999;9:1155-66.
85. Rodriguez C, Patel A, Calle E, Jacob E, Thun M. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-5.
86. Bosze P, Bast R, Berchuck A, Burke HB, Bullet RE, Creasman WT, et al. Consensus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO. Eur J Gynaecol Oncol 2000;21:513-26.
87. Whittemore A, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184-203.
88. Friday K, Dong C, Fontenot R. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type II diabetes. J Clin Endocrinol Metab 2001;86:48-52.
89. Nevitt M, Felson D. Sex hormones and the risk of osteoarthritis in women: epidemiological evidence. Ann Rheum Dis 1996;55:673-6.
90. MacDonald AG, Murphy EA, Capell HA, Bankowska UZ, Ralston SH. Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. Ann Rheum Dis 1994;53:54-7.
91. Sanchez-Guerrero J, Liang MH, Karlson EW, Hunter DJ, Colditz GA. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995;122:430-3.
92. Buyon JP. Hormone replacement therapy in postmenopausal women with systemic lupus erythematosus. J Am Med Womens Assoc 1998;53:13-7.
93. Lieberman D, Kopernik G, Porath A, Lazer S, Heimer D. Subclinical worsening of bronchial asthma during estrogen replacement therapy in asthmatic post-menopausal women. Maturitas 1995;21:153-7.
94. Troisi RJ, Speizer FE, Willett WC, Trichopoulos D, Rosner B. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. A prospective cohort study. Am J Respir Crit Care Med 1995;152(4 Pt 1):1183-8.
95. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 1999;44:1012-20.
96. Davis S. Androgen replacement in women: a commentary. J Clin Endocrinol Metab 1999;84:1886-91.
97. Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol 2000;163:888-93.
98. Arlt W, Callies F, van Vlijmen J, Koehler I, Reincke M, Bidlingmaier M, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999;341:1013-20.
99. Davis S, McCloud P, Strauss B, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36.
100. Shifren J, Braunstein G, Simon J, Casson PR, Buster JE, Redmond GP, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000;343:682-8.
101. Hickok L, Toomey C, Speroff L. A comparison of estrified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol 1993;82:919-24.
102. Siris E, Miller P, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001;286:2815-22.
103. Wilson P, D'Agostino R, Levy D, Belanger A, Silbershatz H, Kannel W. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
104. Gail M, Brinton L, Byar D, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
105. Nekhlyudov L, Fletcher S. Is it time to stop teaching breast self-examination? [editorial] CMAJ 2002;164(13):1851-2.